Cosmo to buy back spin-out Cassiopea
Shares of Ireland-incorporated drugmaker Cosmo Pharmaceuticals (SIX: COPN) fell 4.4% to 76 Swiss francs this morning after it revealed it has agreed to buy back Italy-based Cassiopea (SIX: SKIN), the dermatologics company it spun out in 2015.
Cosmo is launching a public exchange offer in Switzerland to acquire all of the publicly held registered shares of Cassiopea. The exchange ratio per Cassiopea share amounts to 0.467 new Cosmo share.
The exchange ratio is based on the respective 60-day volume-weighted average price (VWAP) share price of each company and reflective of the historical relationship between the market capitalization of Cosmo and that of Cassiopea in the prospective of a “merger of equals”. The exchange ratio corresponds to 37.13 francs per Cassiopea share based on the closing price of Cosmo on October 1, 2021 and 39.02 francs based on the 60-day VWAP of Cosmo as of 1 October 2021.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze